الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 174 |  |  |
| | | from | 174 | | |
Abstract
Alpha fetoprotein, available in clinical practice, is not a sufficiently reliable marker to identify HCC patients, mainly due to its poor sensitivity.
So the need for other tests for the diagnosis and screening of patients at risk of HCC is an important.
Attempts have been made to improve the HCC specificity of AFP by measuring particular glycoforms of the protein. AFP-L3 % and DCP in serum behave independently, they would have the potential to complement each other for the diagnosis and monitoring of HCC.
In this study there was a significant difference between the patients groups and the control group regarding different liver function tests.
Regarding tumor markers, the present study detected a statistically significant elevation of the mean serum level of AFP in HCC groups compared to each of CLD (Chronic liver disease) and control groups (P 0.05), also it showed significant elevation in CLD group compared to controls (P< 0.05).
On testing the value of AFPL3% in this study, the mean AFPL3% was significantly higher in patients with HCC than CLD and control groups (p 0.01). Also it showed a highly significant elevation in CLD group compared to controls (p < 0.01).< Regarding PIVKA-II results, the present study observed a highly statistically significant increase in the mean serum level of PIVKA-II ( p 0.01) in HCC patients compared to each of CLD patients and controls.
Meanwhile, it showed no significant difference (p > 0.05) between CLD patients and controls.